Recombinant Human Endostatin Combined with Vinorelbine-cisplatin Chemotherapy in Treatment of Human Breast Cancer Xenograft in Nude Mice

OBJECTIVE To investigate the anti-angiogenesis and tumor inhibitory effects of recombinant human endostatin(rhES) combined with vinorelbine-cisplatin chemotherapy(NP regimen) on xenograft tumors in nude mice of human breast carcinoma cell MDA-MB-435S. METHODS Forty xenograft nude mice were randomized into 4 groups: NP group (vinorelbine and cisplatin), rhES group (rhES), rhES+NP group(combined treatment as above-mentioned), and control group (normal saline). Inhibitory rate of xenograft and tumor growth curve was calculated and plotted. MVD, VEGF, HIF-1α and P53 were measured by immunohistochemistry. RESULTS Tumor inhibition rate of the rhES+NP group was 64.63%, but that of the NP group was 35.47%. Compared with the other 3 groups, MVD of the rhES+NP group significantly reduced, the difference was statistically significant (P<0.05). HIF-1α, VEGF and P53 of the rhES+NP group was significantly lower than of the control group and the NP group, the difference was statistically significant(P<0.05). CONCLUSION Experiments show that rhES combined with NP regimen can effectively control the tumor growth and decrease tumor MVD in nude mice, which may down-regulated the expression of VEGF and HIF-1α. The mechanism of rhES on P53 needs further study.